CA-CROWN-BIOSCIENCE
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, proudly announces that its global laboratory facilities have successfully passed a series of annual on-site ISO audits, achieving a flawless record with zero discrepancies.
The ISO standards achieved cover:
- ISO 9001 Quality Management
- ISO 14001 Environmental Management
- ISO 45001 Occupational Health and Safety Management Systems
- ISO 20000 IT Service Management
- ISO 27001 IT Security Management Systems
In addition to these certifications, Crown Bioscience’s facilities renewed accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), while its facility in Germany also recently secured approval from the College of American Pathologists (CAP).
Auditing experts lauded the company’s dedication to quality, health and safety, and environmental management, with perfect scores at all facilities.
In parallel to these audits, Crown Bioscience launched its Electronic Laboratory Notebook project, an initiative that digitizes end-to-end laboratory operations and simultaneously strengthens the integrity and precision of laboratory data, further establishing the company as a leader in the field.
The ongoing development and improvement of the ISO management systems and processes emphasize Crown Bioscience's focus on delivering high-quality services, meeting client requirements efficiently, and elevating satisfaction levels for both clients and employees.
Pam Shang, EMBA, Vice President of Global Quality and Regulatory Compliance, said: ‘’We take immense pride in our diligent teams. Their excellent work in the rigorous ISO audits is a testament to our quality and safety commitment, enabling us to serve our customers better on a global scale. We believe that these achievements will bolster our growth and foster ongoing relationships with our existing clients.’’
Crown Bioscience is delighted to receive these recognitions, which highlight the unwavering commitment to excellence. The company foresees that these accomplishments will pave the way for continued success and expansion in preclinical translational science, with a global impact on health and the future of precision medicine.
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology and immuno-oncology. We are the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology, offering over 600 organoid models spanning 22 cancer indications. In addition, we have developed the largest commercially available PDX collection in the world. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 13 facilities across the United States, Europe, and Asia.
For more information or to get in touch, please visit www.crownbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123812070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cessna Citation Ascend Achieves FAA Certification, Bringing Advanced Features to the Most Popular Midsize Business Jet Family6.11.2025 14:15:00 CET | Press release
The Cessna Citation Ascend, designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, achieved a major milestone Wednesday, November 5, as the Federal Aviation Administration (FAA) awarded type certification for the aircraft, with entry into service expected later this year. The aircraft boasts an entirely new cockpit, improved performance and luxurious flat floor cabin, giving customers versatility and flexibility to accomplish their mission. Two flight test articles completed more than 1,000 flight hours and numerous certification tests to achieve FAA certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106032431/en/ Cessna Citation Ascend achieves FAA certification, bringing advanced features to the most popular midsize business jet family (Photo credit: Textron Aviation). “The Citation Ascend’s successful flight test program reflects our teams’ expertise in obtaining FAA certifica
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team6.11.2025 14:00:00 CET | Press release
FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market Equities, the GEM Team follows a high conviction investment philosophy anchored in deep, fundamental research and a private equity-style approach to diligence and ownership. The team invests in high quality companies and those transitioning toward higher quality, leveraging its proprietary insights to identify long-term value creation opportunities across emerging markets. With an active, bottom-up, benchmark-agnostic strategy, the team builds high-conviction, concentrated, quality-focused portfolios that reflect a true ownership mindset. Founded in 2008, FIM Partners is a leading asset manager fo
IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report6.11.2025 14:00:00 CET | Press release
Over 10 billion single-use boxes replaced with reusable packaging in global fresh grocery supply chains IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives. The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders. With operations
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation6.11.2025 14:00:00 CET | Press release
LIBELULATM trial completed enrollment of Central Precocious Puberty (CPP) patients in North and South America, advancing the path for Debio 4326, a triptorelin injectable 12-month extended-release formulation Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of patient enrollment in its open-label, single-arm, multi-center Phase III study (NCT06129539) ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULATM)’. The completion of enrollment is a significant milestone for the development of Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation of the established treatment, triptorelin. The LIBELULATM trial is being conducted across the United States, Argenti
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 13:00:00 CET | Press release
As the U.K. Market Fuels Growing Interest from Domestic and International Activists, Investors Have Adapted their Approach to Gain Access to Boardrooms in Germany and Italy The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what loo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom